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Abstract
OBJECTIVE: To determine whether or not Orlistat ingested prior to a meal causes an increased
appetite response.
STUDY DESIGN: A Review of three randomized controlled trials studies from 2003-2008 that
were in the English language.
DATA RESOURCES: Randomized controlled trials comparing the effect of Orlistat on satiety
were found using PubMed, OVID, and Cochrane databases.
OUTOMES MEASURED: Outcomes measured in the studies were: sensation of appetite,
hunger, fullness, nausea, bloating, heartburn, belching, epigastric burning, and prospective food
consumption. Each study measured individual patient responses using a VAS (visual analogue
scale). Demarchi et al (2004) used a gastric barostat to measure gastric distention and
accommodation to a meal. Both Demarchi (2004) and Goedecke et al (2003) measured plasma
CCK levels and Ellrichmann et al (2008) measured gherlin, GLP-1, and PYY in addition to
CCK. In addition, Ellrichmann et al (2008) used an ultrasound to determine changes in
gallbladder size, and gastric emptying using a C sodium-Octanoate breath test.
RESULTS: Results from both the Demarchi (2004) and Goedecke et al (2003) studies did not
demonstrate any significant increase in appetite or inhibition of anorexogenic hormones with
Orlistat treatment prior to a test meal. The Ellrichmann et al (2008) results demonstrated
decreased gallbladder contractility, increased appetite and food consumption.
CONCLUSIONS: The results of whether Orlistat ingested prior to a meal causes an increased
appetite response has not been shown in two of the three studies reviewed. Future tests should
include varied fat concentrations in a diet and administered to the same subjects with testing
trials in longer duration. Orlistat is still an effective dietary aid in the battle against obesity in
today’s society.
KEY WORDS: Orlistat, appetite, satiety, diet, obesity, treatment, intervention, weight loss
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Introduction
Overweight and obesity is a preventable disease that is associated with significant increases in
both morbidity and mortality. Overweight is defined as having a BMI over 25 and obesity is
having a BMI over 30. Over 68% of adults in the US are overweight,4 and about one-third of
U.S. adults (33.8%) are obese.1 These statistics place obesity and overweight one of the most
common medical conditions in every field of practice. Non-Hispanic black women and
Hispanics have the highest rates of obesity (41.9% and 30.7%)1.
The conditions also impose an additional cost. On average, people who are considered obese
pay $1,429 (42 percent) more in health care costs than normal-weight individuals.1 The total cost
due to obesity in the US is estimated to be $117 billion.5 Physician office visits related to obesity
totaled 62.7 million in 2008.5 A majority of additional costs entailed by the patient may be due to
the complications of obesity such as reproductive, endocrine, gastrointestinal, cardiovascular,
pulmonary, and conditions such as dyslipidemia, metabolic syndrome, cancer, insulin resistance
and Type 2 diabetes.2
The cause of overweight and obesity come from energy imbalance, and there is no single
cause of obesity. In addition, genetic, environmental, behavioral, and socioeconomic factors can
all lead to overweight and obesity. Body weight regulation has both a neural and endocrine
component that effect energy intake and output. Treatment for the condition is centered on these
two components. Behavioral and dietary lifestyle modifications with a focus on less calories, fat
and sugar, along with exercise is the treatment of choice and has the most success long-term.5
Other treatments include pharmacologic such as a lipase inhibitor, appetite suppressants
(adrenergic or norepinephrine/serotonin reuptake inhibitor), and bariatric surgery.
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Appetite and satiety is influenced by many factors that are integrated by the brain, most
importantly in the hypothalamus.3 Hormones, neural afferents, and metabolites may influence the
hypothalamic center. Gut peptide hormones such as ghrelin (from stomach to influence feeding),
glucagon-like peptide-1-(7-36)-amide (GLP-1), peptide YY (PYY), and cholecystokinin (a.ka.
CCK, which is produced in the small intestine) all influence appetite via the vagus nerve. When
there is adequate digestion of dietary triglycerides by pancreatic lipase to produce FFAs (Free
Fatty Acids) anorexigenic hormones, CCK, GLP-1, PYYare released, which in turn, will
increase satiety. In addition, CCK levels directly influence gallbladder emptying
Americans spend $33 billion annually on weight-loss products and services.5 Several weightloss products and services are available in the US market, and diet pills are a popular choice. One
of them is Orlistat which is a lipase inhibitor. A pharmaceutical agent Orlistat, is the only FDA
approved drug to prevent fat absorption in the body. A proposed theory is that Orlistat
accelerates gastric emptying, and inhibits gallbladder motility with reduced secretion of GLP-1,
PYY and CCK. . Therefore, Orlistat may actually cause an increase in appetite and potentially
cause weight-gain, or unchanged weight status. This paper evaluated three randomized
controlled studies (single blind, double blind) comparing the use of a lipase inhibitor to a placebo
in appetite after an ingested meal.

Objective
The objective of this selective EBM review is to determine whether or not Orlistat ingested
prior to a meal causes an increased appetite response.
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Methods
The studies included healthy non-obese men and women aged 19-32 who were pre-prandial
and given Orlistat 120 mg prior to a meal. Included in this analysis were a double-blind
randomized crossover design which compared a five-day regimen of Orlistat 120 mg tablet three
times daily pre-prandial each meal against a visually matched placebo 120 mg; a randomized,
single-blind, placebo-controlled, crossover trial which compared Orlistat 120 mg tablet against a
visually matched placebo 120 mg ingested with a test meal; and a randomized, single-blind,
placebo-controlled, crossover trial which compared Orlistat 120 mg tablet against a visually
matched placebo 120 mg (2 g flour) ingested with a high fat meal after an overnight fast. See
Table 1 for an outline of the patient demographics and characteristics.
Research sources used were PubMed, OVID, and Cochrane databases. Articles for this
systemic review were located by key words “orlistat”, “satiety”, “appetite”, and “weight loss”.
All articles were published in English, in peer reviewed journals, were selected based on the
importance of outcomes and relevance to patients.

Inclusion criteria included randomized

controlled, double blind, single blind, cross-over trials involving healthy non-obese individuals
(BMI<30) aged 19-32. Studies excluded were outcomes not patient oriented such as hormone
and enzyme level responses. To successfully measure patient outcomes, the following statistical
methods were utilized: r2, p-values, AUC, ANOVA, and α level.
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Table 1 – Demographics and Characteristics of included studies
Study

Type

#
Pts

Age

Goedecke6
2003

Randomized,
single-blind,
placebocontrolled,
crossover trial

19

Mean age
21±1.6y

Demarchi7
2004

Double-blind
randomized
cross-over
design

18

Mean age
24±1.11y18-

Randomized,
single-blind,
placebocontrolled,
crossover trial

25

Ellrichmann8
2008

32

20-32
years

Inclusion Criteria

Exclusion
Criteria

W/D

Interventions

• BMI:<30kg/m2
• Absence of
known
metabolic
conditions
• No medications
for chronic
conditions

• Obese pts.
w/ BMI>30

0

• Healthy pts.
with no preexisting
medical
condition

• Currently
on
medication
• Symptoms
or history of
gastrointesti
nal disease
• Drug
allergies
• Major
abdominal
surgery
• History of
GI or
endocrine
disorders

0

(2)
Randomized
trials
separated by 2
wks. where
subjects
ingested test
meal w/
Orlistat
(120mg) or
placebo (2g
flour)
(5) day
regimen of
120 mg
Orlistat tablet
three times
daily preprandial each
meal and a
visually
matched
placebo

BMI in normal
range 19.1-25.0
kg/m2

0

Oral dose of
Orlistat 120
mg ingested
with a test
meal after an
overnight fast

Outcomes Measured
Each study measured individual responses using a VAS (visual analogue scale) and each
study measured a variety of outcomes. Goedecke et al had patients mark their appetite sensation
on a 100 mm line from “not at all full” (0mm) to “extremely full” (100 mm). Ellrichmann et al
measured the effects of Orlistat on sensation of appetite, hunger, fullness, and prospective food
consumption.
Demarchi et al had patients rate gastrointestinal sensation of fullness including bloating,
nausea, heartburn, belching, epigastric burning, discomfort and satiety. There were two test
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periods with the test duration of 5 days and a washout period of 3 weeks. In addition, sensitivity
to gastric distention and accommodation to a meal was measured using a gastric barostat.
Venous blood samples were taken before and after a meal at timed intervals to measure plasma
CCK. Satiety was measured using a VAS with an interval of 5-43 days. During the satiety test,
the patients scored sensations every 5 minutes.
Goedecke et al completed two randomized trials with a recovery period of 2 weeks between
each trial. Satiety and hunger were measured along with blood sampling for CCK levels preprandial and every hour after a test meal for 4 hours. Patients rated motivation to eat such as
hunger, satiety, fullness and prospective consumption prior to a meal and every hour up to 4
hours post meal using a VAS. At 4 hours post-prandial, the patients were given lunch with no
limits on quantity based on their appetite.
Ellrichmann et al trial was conducted on two separate trials. Plasma concentrations of gherlin,
GLP-1, CCK, and PYY were obtained pre-prandial and 2 hours postprandial. Ultrasound
measurements were used to determine Gallbladder size 120 minutes post-prandial, and gastric
emptying was measured using a C sodium-octanoate breath test. A visual analog scale was used
at 15-minute intervals over a period of two hours after ingestion of a meal.

Results
In the Ellrichman et al (2008) study, the administration of Orlistat led to significant inhibition
of gallbladder contractility. In addition, the rise in postprandial plasma concentrations of GLP-1,
PYY, and CCK was significantly lower after Orlistat administration. The mean satiety ratings
were reduced by 15% after Orlistat treatment and fullness was lowered by 12%. Orlistat
treatment caused a significant increase in appetite (24%) and prospective food consumption
(31%). There was a linear relationship between gallbladder emptying and the plasma levels of
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CCK, PYY, and GLP-1. A decrease in gallbladder contractility decreased levels of the plasma
anorexigenic hormones. In addition, there was positive correlation between the ratings of satiety
and fullness and gallbladder emptying, and hunger and food consumption were inversely related.
There was statistical significance between satiety and incremental concentrations of CK (r2=0.41,
P<0.0001) and GLP-1 (r2=0.14, P=0.0064). The rise in postprandial plasma concentration of
GLP-1, PYY, and CCK was significantly lower after Orlistat administration.8 The statistical
significance is demonstrated in Table 2.

Table 2: One-Way ANOVA statistical analysis of GLP-1, PYY, CCK and Ghrelin plasma
concentrations placebo vs. administration of Orlistat8
Hormone

Differences Between
Experiments

Differences Over Time

GLP-1

p=0.015

p<0.0001

Differences due to
Interaction of
Experiment and Time
p=0.002

PYY

p=0.16

p<0.0001

p<0.001

CCK

p<0.0001

p<0.0001

p<0.0001

Ghrelin

p= 0.77

p<0.0001

p=0.18

In the Goedecke et al study, Orlistat was not shown to alter the ratings of hunger, satiety,
prospective consumption or fullness while examining changes over time (Table 3). There were
no differences in post-test meal intake between the Orlistat and placebo trials. The plasma CCK
response showed no significant difference in response to the high-fat meal with Orlistat
compared to placebo administration. However, the study showed variability in CCK
administration due to variability in body fatness. BMI correlated negatively with plasma CCK
for both the Orlistat and placebo trials (R=-0.690, P=0.001 and R=-0.649, P=0.003 respectively
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Table 3: Area under the curve for appetite scores in response to the high-fat test meal with
Orlistat and placebo administration6
Orlistat

Placebo

P-value

Hunger (mm x 4hrs)

14,866 ±5324

15,021 ±5376

0.848

Satiety (mm x 4 hrs)

13,378 ±4626

13,208 ±5516

0.755

Fullness (mm x 4hrs)

6,898 ±3422

7,675 ±4293

0.360

16,697 ±4259

16,631 ±4081

0.924

Prospective Intake (mm x 4 hrs)

In the Demarchi et al double-blind, randomized, crossover study, sensitivity to gastric
distension and gastric accommodation to a meal was studied using a gastric barostat. Two test
periods of 5 days each were completed. The fasting perception and discomfort thresholds during
fasting distentions with Orlistat did not differ significantly from the placebo. The area under the
curve (AUC) of perception scores during fasting isobaric distentions with the placebo and the
Orlistat pre-treatment showed no significant differences as outlined in Table 4.

Table 4: Area under the curve of perception scores in response during fasting isobaric
gastric distentions with placebo and Orlistat pre-treatment7
Placebo

Orlistat

Fullness

70±11

80±9

Bloating

81±12

78±10

Satiety

76±16

75±10

Discomfort

78±10

77±11

Belching

44±12

28±7

Nausea

35±13

23±8

Epigastric burning

66±11

64±10

Heartburn

42±13

31±10
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During postprandial distentions the postprandial pressure-volume curves did not differ between
both treatment groups. In addition, treatment with Orlistat, first perception and discomfort
thresholds were not significantly altered as outlined in Table 5.

Table 5: Area under the curve (AUC) of perception scores during postprandial isobaric
gastric distentions, with placebo and Orlistat pre-treatment (no significant differences)7
Placebo

Orlistat

Fullness

94±13

70±11

Bloating

95±13

70±11

Satiety

98±14

70±13

Discomfort

97±13

70±11

Belching

47±18

70±10

Nausea

54±16

70±13

Epigastric burning

63±13

70±12

Heartburn

37±13

70±12

Serum CCK analysis after Orlistat pre-treatment demonstrated lower levels when compared to
the placebo. CCK levels, P=0.09, and preprandial AUC, P=0.06. In post-prandial CCK levels
(P<0.01) and the postprandial AUC (P=.0.3) were significantly lower after orlistat pre-treatment.
A satiety test both after the placebo and Orlistat treatments showed a high correlation between
satiety scores and the amount of calories ingested (R>0.95, P<0.0001). Pre-treatment with
Orlistat did not significantly alter the amount of calories ingested until maximum satiety as
compared to placebo shown in Table 6.
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Table 6: Area under the curve (AUC) of perception scores during the satiety drink test,
with placebo and orlistat pre-treatment7
Placebo

Orlistat

Fullness

207±15

190±13

Bloating

160±21

149±17

Satiety

148±11

135±10

Discomfort

119±24

140±19

Belching

76±14

87±17

Nausea

61±11

55±16

Epigastric burning

40±10

59±15

Heartburn

27±8

34±10

Discussion
The articles used in this EBM review demonstrate that the control of gastric sensitivity and
gastric accommodation to a meal is incompletely understood7. Lipid digestion and subsequent
release of CCK and activation of CCK B receptors are key factors in gastric emptying and
sensitivity.
There were contradictory findings between the studies that examined to effects of Orlistat on
satiety. Both the Demarchi et al (2004) and Goedecke et al (2003) did not demonstrate findings
that an oral lipase inhibitor, Orlistat, would significantly reduce plasma CCK release to influence
gastric sensitivity with sensation of hunger or satiety in response to a meal. Although lowered
CCK levels were observed with Orlistat pre-treatment prior to a meal in these studies, the
medication had no effect on calories consumed, gastric distention, and failed to elicit any
symptoms of increased appetite.
On the other hand, Ellrichmann (2008) did show increased appetite with the administration of
Orlistat with the relationship of inhibition of CCK, GLP-1, and PYY release. The tests
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demonstrated Orlistat accelerates gastric emptying. Ghrelin, another anorexigenic hormone, was
unaffected. The experimental testing took place for up to 120 minutes only versus the other
studies consisted of a longer length time period for testing.

Conclusion
Two of the three studies reviewed demonstrate overall, that the use of Orlistat does not cause
an increase in appetite in healthy patients. One study showed an increase in appetite but the study
duration was a shorter time period limited to just 2 hours which places the validity of the study in
question. The response to symptoms related to satiety was subjective using the VAS and were
subject to potential varied responses based on the patient’s tolerance and interpretation. In
addition, varied results between the studies may also be directly correlated to the diet the patients
were given, where fat content plays an important role in measuring the body’s response. Future
studies could include varied amounts of fat content in test meals and measure responses in both
anorexigenic hormones and subjective ratings by the patients.
If continued to use as directed, Orlistat can be an effective weight loss regimen adjunct to
healthy lifestyle changes.
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